|
gptkbp:instanceOf
|
gptkb:drug
antidepressant
norepinephrine reuptake inhibitor
|
|
gptkbp:approvedBy
|
gptkb:FDA
2008
|
|
gptkbp:ATCCode
|
N06AX23
|
|
gptkbp:availableOn
|
extended-release tablet
|
|
gptkbp:bioavailability
|
80%
|
|
gptkbp:brand
|
gptkb:Khedezla
gptkb:Pristiq
|
|
gptkbp:CASNumber
|
93413-62-8
|
|
gptkbp:category
|
antidepressant
psychiatric medication
SNRI
|
|
gptkbp:chemicalFormula
|
C16H25NO2
|
|
gptkbp:compatibleWith
|
children
|
|
gptkbp:contraindication
|
concurrent use with MAO inhibitors
hypersensitivity to desvenlafaxine
|
|
gptkbp:developedBy
|
gptkb:Wyeth
|
|
gptkbp:drugClass
|
norepinephrine reuptake inhibitor
|
|
gptkbp:eliminationHalfLife
|
11 hours
|
|
gptkbp:excretion
|
kidneys
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
desvenlafaxine
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits reuptake of serotonin and norepinephrine
|
|
gptkbp:metabolism
|
gptkb:CYP3A4
gptkb:venlafaxine
|
|
gptkbp:molecularWeight
|
263.38 g/mol
|
|
gptkbp:notRecommendedFor
|
bipolar disorder
anxiety disorders
|
|
gptkbp:patentExpired
|
2017
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescribes
|
adults
|
|
gptkbp:proteinBinding
|
30%
|
|
gptkbp:relatedTo
|
gptkb:venlafaxine
|
|
gptkbp:riskFactor
|
gptkb:serotonin_syndrome
hypertension
increased suicidal thoughts in young adults
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
constipation
dizziness
insomnia
dry mouth
hyperhidrosis
|
|
gptkbp:usedFor
|
gptkb:major_depressive_disorder
|
|
gptkbp:bfsParent
|
gptkb:venlafaxine
gptkb:Serotonin-norepinephrine_reuptake_inhibitors
gptkb:Venlafaxine
gptkb:serotonin-norepinephrine_reuptake_inhibitors
gptkb:SNRIs
|
|
gptkbp:bfsLayer
|
7
|